Two-Stage Screening Model Improves OSA Detection in Primary Care
A two-stage screening model using the STOP-BANG questionnaire (SBQ) followed by automated home sleep apnea testing (HSAT) enhances obstructive sleep apnea (OSA) detection in primary care.
Immunovant's IMVT-1402 Shows Promise in Graves' Disease Treatment
Immunovant is launching a late-stage clinical trial for IMVT-1402, a novel anti-FcRn agent, offering a potential new treatment for Graves' disease.
Enhertu Demonstrates Significant Activity in HER2-Positive Metastatic Breast Cancer with Brain Metastases
Enhertu showed substantial clinical activity in HER2-positive metastatic breast cancer patients, including those with active brain metastases, based on a post-hoc analysis.
AOH1996: Novel Cancer Drug Selectively Targets Tumors, Spares Healthy Cells in Preclinical Studies
AOH1996, a novel drug developed by City of Hope researchers, targets a unique form of PCNA present in cancer cells, disrupting tumor growth.
Anlotinib and Penpulimab Combination Shows Promise in Advanced Hepatocellular Carcinoma
The Phase III APOLLO trial demonstrated that anlotinib combined with penpulimab significantly improved progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (aHCC).
AnaCardio's AC01 Demonstrates Progress in Heart Failure Clinical Trials
AnaCardio completed the AC01-FE study in the US, finding AC01 safe and well-tolerated in healthy volunteers under fed and fasted conditions.
Oncology Accelerated Approvals Often Based on Non-Comparative Trials
A recent study highlights that oncology accelerated approvals frequently rely on non-comparative trials assessing response rates, raising questions about long-term efficacy.
Immutep's Efti Shows Promise in Neoadjuvant Soft Tissue Sarcoma Treatment
Immutep's EFTISARC-NEO Phase II trial evaluates eftilagimod alpha (efti) with radiotherapy and pembrolizumab in soft tissue sarcoma patients.
FDA Grants Orphan Drug Designation to CF33-hNIS for Cholangiocarcinoma
The FDA has granted orphan drug designation to CF33-hNIS (Vaxinia) for treating cholangiocarcinoma, a rare cancer with limited therapeutic options.
Aligos Therapeutics' ALG-055009 Shows Promise in Phase IIa MASH Trial
Aligos Therapeutics announced positive results from its Phase IIa HERALD trial of ALG-055009 for MASH, demonstrating notable liver fat reduction.
FDA Approves First Treatments for Niemann-Pick Type C, Offering New Hope to Patients
The FDA has approved two new treatments for Niemann-Pick Type C, a rare and fatal genetic disorder, marking a significant milestone for patients and families.
Phase 3 Gliofocus Trial Aims to Improve Outcomes in MGMT Unmethylated Glioblastoma with Niraparib
The phase 3 Gliofocus trial (NCT06388733) is evaluating niraparib versus temozolomide in newly diagnosed MGMT unmethylated glioblastoma patients.
Teva's TEV-749 Shows Promise in Schizophrenia Treatment with No PDSS Incidence
Teva's TEV-749, a once-monthly subcutaneous olanzapine injection, significantly improved schizophrenia symptoms in a Phase 3 trial, meeting its primary endpoint.
Vietnam Launches Nationwide Dengue Fever Vaccination Program with Qdenga
Vietnam has initiated a nationwide dengue fever vaccination program, the first of its kind in the country, targeting individuals aged four and above.
FDA Grants Fast Track Designation to Elevation Oncology's EO-3021 for Gastric and GEJ Cancers
The FDA has granted Fast Track designation to EO-3021 for advanced or metastatic gastric and gastroesophageal junction (GEJ) cancer expressing Claudin 18.2.
APE1's Role in DNA Repair Could Influence Cancer Clinical Trials
Researchers have elucidated the functional role of APE1, a protein crucial for initiating DNA damage repair, potentially impacting cancer survival rates.
pGTI Applied in STAR-JIA Trial to Assess Steroid Toxicity in Children with Juvenile Idiopathic Arthritis
The STAR-JIA trial will use Steritas' Pediatric Glucocorticoid Toxicity Index (pGTI) to compare intravenous versus oral glucocorticoids in children with Juvenile Idiopathic Arthritis (JIA).
FDA Approvals for Breast Cancer Drugs: Clinical Benefits, Development Time, and Pricing Analysis
The FDA approved 26 unique cancer drugs for breast cancer across 42 indications between 2000 and 2023, with a median development time of 7.8 years.
New HER2 Test Could Expand Trastuzumab Deruxtecan Eligibility for Lung Cancer Patients
A novel, more sensitive test for HER2 protein in lung cancer tissues has been developed, potentially expanding the number of patients eligible for trastuzumab deruxtecan (T-DXd).
Deuruxolitinib Demonstrates Efficacy in Hair Regrowth and Improves Patient Well-being in Severe Alopecia Areata
Data from the THRIVE-AA1 and THRIVE-AA2 trials showed 31% of patients on deuruxolitinib achieved significant hair regrowth, with 95.7% of responders reporting satisfaction with their hair by week 24.